Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 6 studies | 31% ± 17% | |
ciliated cell | 5 studies | 32% ± 9% | |
endothelial cell | 4 studies | 18% ± 2% | |
basal cell | 4 studies | 23% ± 7% | |
secretory cell | 3 studies | 21% ± 6% | |
classical monocyte | 3 studies | 17% ± 2% | |
abnormal cell | 3 studies | 20% ± 1% | |
transit amplifying cell | 3 studies | 25% ± 12% | |
goblet cell | 3 studies | 19% ± 4% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 8333.90 | 1445 / 1445 | 100% | 70.03 | 183 / 183 |
pancreas | 100% | 5261.26 | 328 / 328 | 100% | 56.83 | 178 / 178 |
prostate | 100% | 9775.47 | 245 / 245 | 100% | 79.67 | 502 / 502 |
stomach | 100% | 6382.70 | 359 / 359 | 100% | 60.60 | 286 / 286 |
uterus | 100% | 8184.98 | 170 / 170 | 100% | 60.40 | 459 / 459 |
thymus | 100% | 9123.15 | 653 / 653 | 100% | 73.76 | 604 / 605 |
breast | 100% | 7775.18 | 459 / 459 | 100% | 61.14 | 1116 / 1118 |
skin | 100% | 8875.93 | 1809 / 1809 | 100% | 52.91 | 471 / 472 |
intestine | 100% | 8160.06 | 966 / 966 | 100% | 62.77 | 525 / 527 |
bladder | 100% | 8146.19 | 21 / 21 | 100% | 59.38 | 502 / 504 |
ovary | 100% | 7435.22 | 180 / 180 | 99% | 53.21 | 427 / 430 |
lung | 100% | 7881.57 | 577 / 578 | 99% | 57.77 | 1148 / 1155 |
adrenal gland | 100% | 8017.01 | 258 / 258 | 99% | 76.58 | 228 / 230 |
kidney | 100% | 6761.92 | 89 / 89 | 99% | 38.95 | 891 / 901 |
brain | 99% | 5985.31 | 2628 / 2642 | 99% | 54.27 | 700 / 705 |
liver | 100% | 5070.29 | 226 / 226 | 98% | 36.71 | 399 / 406 |
adipose | 100% | 7554.55 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7383.25 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 48.37 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 61.52 | 29 / 29 |
muscle | 100% | 5239.45 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 9794.73 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 58.34 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 40.04 | 1 / 1 |
heart | 99% | 4337.02 | 855 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 8376.02 | 915 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0032508 | Biological process | DNA duplex unwinding |
GO_0006281 | Biological process | DNA repair |
GO_0032204 | Biological process | regulation of telomere maintenance |
GO_0006449 | Biological process | regulation of translational termination |
GO_0071044 | Biological process | histone mRNA catabolic process |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_0000184 | Biological process | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay |
GO_0006260 | Biological process | DNA replication |
GO_0061158 | Biological process | 3'-UTR-mediated mRNA destabilization |
GO_0006406 | Biological process | mRNA export from nucleus |
GO_0032201 | Biological process | telomere maintenance via semi-conservative replication |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_1905746 | Biological process | positive regulation of mRNA cis splicing, via spliceosome |
GO_0044770 | Biological process | cell cycle phase transition |
GO_0000956 | Biological process | nuclear-transcribed mRNA catabolic process |
GO_0061014 | Biological process | positive regulation of mRNA catabolic process |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0035145 | Cellular component | exon-exon junction complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000932 | Cellular component | P-body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0044530 | Cellular component | supraspliceosomal complex |
GO_0000781 | Cellular component | chromosome, telomeric region |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0004386 | Molecular function | helicase activity |
GO_0003724 | Molecular function | RNA helicase activity |
GO_0003682 | Molecular function | chromatin binding |
GO_0044877 | Molecular function | protein-containing complex binding |
GO_0036121 | Molecular function | double-stranded DNA helicase activity |
GO_0042162 | Molecular function | telomeric DNA binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0005515 | Molecular function | protein binding |
GO_0016887 | Molecular function | ATP hydrolysis activity |
Gene name | UPF1 |
Protein name | UPF1 RNA helicase and ATPase UPF1 Regulator of nonsense transcripts 1 variant Regulator of nonsense transcripts 1 (EC 3.6.4.12) (EC 3.6.4.13) (ATP-dependent helicase RENT1) (Nonsense mRNA reducing factor 1) (NORF1) (Up-frameshift suppressor 1 homolog) (hUpf1) |
Synonyms | KIAA0221 RENT1 hCG_37042 |
Description | FUNCTION: RNA-dependent helicase required for nonsense-mediated decay (NMD) of aberrant mRNAs containing premature stop codons and modulates the expression level of normal mRNAs . Is recruited to mRNAs upon translation termination and undergoes a cycle of phosphorylation and dephosphorylation; its phosphorylation appears to be a key step in NMD . Recruited by release factors to stalled ribosomes together with the SMG1C protein kinase complex to form the transient SURF (SMG1-UPF1-eRF1-eRF3) complex . In EJC-dependent NMD, the SURF complex associates with the exon junction complex (EJC) (located 50-55 or more nucleotides downstream from the termination codon) through UPF2 and allows the formation of an UPF1-UPF2-UPF3 surveillance complex which is believed to activate NMD . Phosphorylated UPF1 is recognized by EST1B/SMG5, SMG6 and SMG7 which are thought to provide a link to the mRNA degradation machinery involving exonucleolytic and endonucleolytic pathways, and to serve as adapters to protein phosphatase 2A (PP2A), thereby triggering UPF1 dephosphorylation and allowing the recycling of NMD factors . UPF1 can also activate NMD without UPF2 or UPF3, and in the absence of the NMD-enhancing downstream EJC indicative for alternative NMD pathways . Plays a role in replication-dependent histone mRNA degradation at the end of phase S; the function is independent of UPF2 . For the recognition of premature termination codons (PTC) and initiation of NMD a competitive interaction between UPF1 and PABPC1 with the ribosome-bound release factors is proposed . The ATPase activity of UPF1 is required for disassembly of mRNPs undergoing NMD . Together with UPF2 and dependent on TDRD6, mediates the degradation of mRNA harboring long 3'UTR by inducing the NMD machinery (By similarity). Also capable of unwinding double-stranded DNA and translocating on single-stranded DNA . . |
Accessions | A0A059XG67 A0A059XBJ1 A0A8A5YNF9 A0A059XBJ6 A0A8A5YP40 A0A059XG73 A0A994J4L7 A0A059XAM1 ENST00000599848.5 [Q92900-1] ENST00000262803.10 [Q92900-2] A0A059XAL2 A0A994J597 A0A8A5YPS5 A0A8A5YNG5 ENST00000704678.1 A0A059X4U2 Q92900 A0A059XAL6 A0A024R7L5 ENST00000704676.1 ENST00000704677.1 A0A994J773 A0A059XAJ5 |